Live Chat

CFD's zijn complexe instrumenten en gaan gepaard met een hoog risico snel kapitaal te verliezen als gevolg van hefboommechanismen. 74% an de retailbeleggers lijdt verlies op de handel in CFD's met deze aanbieder. U dient zorgvuldig te overwegen of u begrijpt hoe CFD's werken en of u het zich kunt veroorloven om hoge risico's te nemen op het verliezen van uw kapitaal.

Close

Handelen Novavax NVAX

Novavax live grafieken

instrument_fundamentals

Weekly Search
Weekly
Daily
Datum Sluit Verandering % verandering Openen Piek Bodem

Laatste marktnieuws

Frances Wang 2024 Dec 19, 16:00

Analyst revises Amazon stock forecast following major 'moonshot' initiative

Stocks
Frances Wang 2024 Dec 19, 16:00

Stock market today: 3 bullish stocks that J.P. Morgan Just Upgraded

Stocks
Frances Wang 2024 Dec 19, 16:00

Bitcoin news today: Jerome Powell Says Fed Won’t Hold Bitcoin

Cryptocurrencies
Frances Wang 2024 Dec 19, 16:00

Gold performance and prediction: how high could gold price go?

Commodities
UK GDP
Dyogenes Diniz 2024 Dec 19, 16:00

Week ahead: Last full week of 2024 in the Financial Markets

Forex Indices
Frances Wang 2024 Dec 18, 16:00

Stock market today: Nasdaq Hits Record Highs as Tesla Achieves New Peaks

Stocks
Frances Wang 2024 Dec 18, 16:00

Dow Jones tumbles 1,100 points: why did the stock market go down today?

Stocks
Frances Wang 2024 Dec 18, 16:00

Super Micro Shares Drop 8% Following Nasdaq 100 Removal

Stocks

Info

Spread

0.07

Spread (%)

0.8083 %

Hefboom

1:5

Dagrente kopen

-0.0597 %

Dagrente verkopen

-0.0292 %

Valuta

USD

Openingstijden

Markt gesloten

Maandag

14:31 - 20:59

Dinsdag

14:31-17:59

Donderdag

14:31-20:59

Vrijdag

14:31-20:59

instr__analysis_statistics

Openen

---

Vorige Sluiten

---

52-weekse hoog/laag

--- – ---

Beurswaarde

1393609344

Uitstaande aandelen

160184992

Datum winstcijfer (volgende)

2019-05-10

Div. rend.

2019-05-10

Ex-dividenddatum

Jaarlijks verwachte dividendpercentage

0

Jaarlijks verwachte dividendrendement

0

Winst per aandeel

-2.19

Meer informatie over dit instrument

Novavax Novavax Inc
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Gerelateerde instrumenten

Activa
Verkoop
Koop
% verandering
Gerelateerde instrumenten
Trustpilot
Live Chat